Orexo to Participate in Pareto Securities' 15th Annual Healthcare Conference
Orexo AB (Publ.), known for its innovative contributions to the pharmaceutical field, is thrilled to announce its participation in the upcoming Pareto Securities' 15th Annual Healthcare Conference. This esteemed event is set to take place soon, offering a platform for leaders in the industry to discuss the latest advancements in healthcare.
Details of the Event and Presentation Highlights
The conference will be hosted at the Downtown Camper by Scandic, located at Brunkebergstorg 9. During the event, Robert Rönn, Orexo's Senior Vice President and Head of R&D, will share insights about the company's innovative journey and future plans. His presentation is scheduled for 2:25 to 2:45 PM CET in the Event Small room. Attendees will also have the chance to meet one-on-one with both Robert Rönn and Lena Wange, the Director of Investor Relations.
About Orexo: A Leader in Pharmaceutical Innovation
With nearly 30 years of experience, Orexo has established itself as a leading Swedish pharmaceutical company. The organization is committed to developing advanced treatment options that address significant health issues. Orexo primarily focuses on creating medications for opioid use disorders while also exploring new therapeutic areas in collaboration with top firms worldwide. In the last reported fiscal year, Orexo achieved impressive sales of SEK 624 million and is supported by a dedicated team of 126 employees. As a publicly traded company on Nasdaq Stockholm's main exchange, Orexo is also listed on the OTCQX under the ticker ORXOY in the United States.
Innovative Technology: AmorphOX®
One of Orexo's significant technological breakthroughs is AmorphOX, an advanced drug delivery system designed to improve the effectiveness of medications. This unique formulation combines drugs with carrier materials to create a stable powder. The resulting particles exhibit excellent chemical stability and enable rapid dissolution, making them highly effective for a wide variety of active substances. Clinical studies have confirmed its efficacy, showing enhanced absorption and quick release of drugs into the body.
Contact Information for Orexo
For any inquiries, please reach out to Orexo's IR & Communications Director, Lena Wange, at +46 18 780 88 00 or via email at Lena.Wange@orexo.com.
Stay Connected with Orexo
To learn more about Orexo and its innovative products, visit www.orexo.com. For the latest news and updates, follow Orexo on social media platforms such as X, LinkedIn, and YouTube.
Frequently Asked Questions
1. What is the purpose of Orexo's participation in the conference?
Orexo aims to showcase its latest innovations in pharmaceutical treatments and engage with industry stakeholders.
2. Who will be representing Orexo at the conference?
Robert Rönn, Senior Vice President and Head of R&D, along with Director of Investor Relations, Lena Wange.
3. What innovative technology does Orexo utilize for drug delivery?
Orexo employs AmorphOX® technology, enhancing drug stability and absorption efficiency.
4. How can I learn more about Orexo's products and updates?
You can visit Orexo's official website at www.orexo.com and follow their social media channels.
5. What is the significance of this conference for Orexo?
This conference presents an opportunity for Orexo to network, share insights, and discuss advancements within the pharmaceutical sector.
